4-(phenylazo)benzenesulfonyl chloride | 102840-82-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 偶氮苯
• 英文名称: 4-(phenylazo)benzenesulfonyl chloride
• 英文别名: (E)-4-(phenyldiazenyl)benzene-1-sulfonyl chloride；p-phenylazobenzenesulfonyl chloride；4-phenylazo-benzenesulfonyl chloride；4-Phenylazo-benzolsulfonylchlorid；Azobenzol-sulfonylchlorid-(4)；Azobenzol-sulfonsaeure-(4)-chlorid
• CAS: 102840-82-4
• 化学式: C₁₂H₉ClN₂O₂S
• 分子量: 280.735
• InChiKey: UEAZPVORQYDKHZ-CCEZHUSRSA-N

物化性质

• 熔点：
  124.4-125 °C
• 沸点：
  418.9±28.0 °C(Predicted)
• 密度：
  1.35±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.03
• 重原子数：
  18.0
• 可旋转键数：
  3.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  58.86
• 氢给体数：
  0.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  4-(phenylazo)benzenesulfonyl chloride 在 吡啶 、 盐酸 、 tin 、 水 作用下， 生成 磺胺吡啶
  参考文献：
  名称：

  SULFANILAMIDES FROM p-AZOBENZENESULFONYL CHLORIDE¹

  摘要：

  DOI：

  10.1021/jo01179a007
• 作为产物：
  描述：

  偶氮苯 在 chlorosulphuric acid 作用下， 生成 4-(phenylazo)benzenesulfonyl chloride
  参考文献：
  名称：

  SULFANILAMIDES FROM p-AZOBENZENESULFONYL CHLORIDE¹

  摘要：

  DOI：

  10.1021/jo01179a007

文献信息

• Photoswitch inhibitors of α-chymotrypsin—increased substitution and peptidic character in peptidomimetic boronate esters
  作者：David Pearson、Andrew D. Abell

  DOI：10.1039/b609320p

  日期：——

  A series of peptidomimetic boronate esters containing the photoisomerisable azobenzene group has been synthesised and assayed against the serine protease α-chymotrypsin. Compounds with borophenylalanine inhibition groups were found to be inhibitors with micromolar activity, while those with aryl boronate inhibition groups were inactive. Selected compounds were isomerised by UV or visible light to obtain enriched states of the (Z) or (E) isomers, respectively, and assayed. A change in activity on photoisomerisation was observed, however some decomposition of the boronate group on irradiation was also observed, limiting reversibility.

  一系列含有光异构化偶氮苯基团的多肽模拟硼酸酯被合成并用于测试对丝氨酸蛋白酶α-糜蛋白酶的抑制作用。含有硼苯丙氨酸抑制基团的化合物表现出微摩尔级别的活性，而那些含有芳基硼酸酯抑制基团的化合物则无活性。选定的化合物通过紫外或可见光进行异构化，分别获得富含(Z)或(E)异构体的状态，并进行测试。观察到光异构化后活性发生变化，但在照射过程中也观察到硼酸酯基团的分解，这限制了反应的可逆性。
• Synthesis and antiproliferative activity of sulfonamide-based peptidomimetic calpain inhibitors
  作者：Isaac O. Donkor、Jin Xu、Jiuyu Liu、Keyuna Cameron

  DOI：10.1016/j.bmc.2020.115433

  日期：2020.5

  abnormalities such as neurodegenerative disorders, cataract, and cancer. Therefore, calpain inhibitors are of interest as potential therapeutic agents. We have synthesized four new sulfonamide-based peptidomimetic compounds 2-5 as inhibitors of μ-calpain that incorporate (E)-1-(phenyl)-2-phenyldiazene and (E)-1-(phenyl)-2-phenylethene functionalities as the N-terminal capping groups of the inhibitors. Compound

  钙蛋白酶是一个半胱氨酸蛋白酶的保守家族，其中包括几种同工型，其中μ–calpain和m-calpain在哺乳动物细胞中分布最广。钙蛋白酶已牵涉到正常的生理过程以及细胞异常，例如神经退行性疾病，白内障和癌症。因此，钙蛋白酶抑制剂作为潜在的治疗剂是令人感兴趣的。我们已合成了四个新基于磺酰胺的拟肽化合物2 - 5为μ钙蛋白酶掺入抑制剂（ë）-1-（苯基）-2- phenyldiazene和（ë）-1-（苯基）-2- phenylethene功能如抑制剂的N末端封端基团。化合物5与相对于μ-钙蛋白酶，K i值为9 nM是该组中最有力的成员。根据CLogP估计，与MDL28170相比，预测该化合物具有更高的亲脂性。与体外黑色素瘤细胞系（A-375和B-16F1）和PC-3前列腺癌细胞相比，它们具有中等至良好的抗增殖活性。另外，在Matrigel细胞侵袭测定中，该组中的一个成员（化合物3）以2μM的浓度抑制了DU-145细胞侵袭80％。
• [EN] ALKENYL- AND ALKYNYL-CONTAINING METALLOPROTEASE INHIBITORS<br/>[FR] INHIBITEURS DE METALLOPROTEASES, CONTENANT ALCENYLE ET ALCYNALE
  申请人：PROCTER & GAMBLE

  公开号：WO2000051975A1

  公开（公告）日：2000-09-08

  Disclosed are compounds which are inhibitors of metalloproteases and which are effective in treating conditions characterized by excess activity of these enzymes. In particular, the compounds have a structure according to Formula (I) where X, W, Z, A, G, R?1, R2, R3, R4, R5, R5'¿ and k have the meanings described in the specification. This invention also includes optical isomers, diastereomers and enantiomers of said formula, and pharmaceutically-acceptable salts, biohydrolyzable amides, esters, and imides thereof. Also described are pharmaceutical compositions comprising these compounds, and methods of treating or preventing metalloprotease-related maladies using the compounds or the pharmaceutical compositions.

  本发明涉及一种金属蛋白酶抑制剂化合物，其能够有效治疗由这些酶过度活性引起的疾病。特别地，该化合物具有如公式（I）所示的结构，其中X，W，Z，A，G，R1，R2，R3，R4，R5，R5'和k具有规范中描述的含义。本发明还包括该公式的光学异构体、对映异构体和对映体，以及其药学上可接受的盐、生物水解酰胺、酯和亚酰胺。还描述了包含这些化合物的药物组合物，以及使用这些化合物或药物组合物治疗或预防金属蛋白酶相关疾病的方法。
• Dihetero-substituted metalloprotease inhibitors
  申请人：The Procter & Gamble Company

  公开号：US20030225074A1

  公开（公告）日：2003-12-04

  Disclosed are compounds which are inhibitors of metalloproteases and which are effective in treating conditions characterized by excess activity of these enzymes. In particular, the compounds have a structure according to the following Formula (I): 1 where J, M, Q, T, W, X, Z, R 1 , R 2 , R 3 , R 4 , R 4′ , R 5 , R 6 , R 6′ , R 7 , m, and n have the meanings described in the specification. This invention also includes optical isomers, diastereomers and enantiomers of the formula above, and pharmaceutically-acceptable salts, biohydrolyzable amides, esters, and imides thereof. Also disclosed are pharmaceutical compositions comprising these compounds, and methods of treating or preventing metalloprotease-related maladies using the compounds or the pharmaceutical compositions.

  本发明涉及一种金属蛋白酶抑制剂化合物，用于治疗由这些酶的过度活性引起的疾病。特别地，该化合物具有以下式(I)的结构：其中J、M、Q、T、W、X、Z、R1、R2、R3、R4、R4'、R5、R6、R6'、R7、m和n在规范中有所描述。本发明还包括该式的光学异构体、对映异构体和对映体，以及其药物可接受的盐、生物可水解的酰胺、酯和亚酰酰胺。还公开了包含这些化合物的药物组合物，以及使用该化合物或药物组合物治疗或预防金属蛋白酶相关疾病的方法。
• Chemical compounds
  申请人：Adams Leroy Jerry

  公开号：US20050004142A1

  公开（公告）日：2005-01-06

  Furo- and thienopyrimidine derivatives, which are useful as TIE-2 and/or VEGFR-2 inhibitors are described herein. The described invention also includes methods of making such furo- and thienopyrimidine derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.

  本文描述了作为TIE-2和/或VEGFR-2抑制剂有用的呋喃和噻吩嘧啶衍生物。所述发明还包括制备这种呋喃和噻吩嘧啶衍生物的方法，以及使用它们治疗增殖过度性疾病的方法。